Loading organizations...
§ Private Profile · 2 Richmond Square, Providence, RI 02906
Biotechnology company developing cell encapsulation and stem cell therapies for neurological and metabolic diseases.
Key people at Cytotherapeutics, Inc..
Founded in 1989 by scientific founder Patrick Aebischer, Cytotherapeutics is a Providence, Rhode Island-based biotechnology company developing cell encapsulation and transplantation technology for therapeutic applications. Under the leadership of President and CEO Richard Rose, the organization focuses on creating encapsulated cell therapies and stem cell-based treatments for neurological and metabolic conditions, including Parkinson's disease and insulin-dependent diabetes. Utilizing foundational research from Brown University and Washington University in Saint Louis, the enterprise completed an initial public offering in March 1992 and raised $28.62 million in funding. Throughout its operational history, the firm expanded its portfolio by acquiring the gene therapy company Modex and eventually selling its encapsulated cell assets to Neurotech SA. Following a strategic shift toward stem cell research, the business entered into a merger agreement with StemCells Incorporated in August 1997.
Key people at Cytotherapeutics, Inc..
Cytotherapeutics, Inc. was a biotechnology company founded in 1989 that developed cell encapsulation and transplantation technology for therapeutic applications, such as treating Parkinson's disease with dopamine-secreting encapsulated mouse cells and insulin-dependent diabetes with encapsulated porcine pancreatic islet cells.[1] The company, headquartered initially in Providence, Rhode Island, raised $28.62M in funding, went public via IPO in 1992, and later pivoted from encapsulated cell technology (ECT) to stem cell-based therapies before undergoing significant restructuring, including selling ECT assets to Neurotech and relocating operations to Sunnyvale, California.[1][2] It served patients with neurological and metabolic disorders by addressing unmet needs in cell-based treatments where traditional therapies fell short, though growth momentum stalled amid financial pressures and operational shifts, leading to staff reductions from a peak of 125 employees.[2][5]
Cytotherapeutics emerged from academic research, with its core technology rooted in encapsulation studies at Brown University and pancreas islet cell isolation at Washington University in St. Louis; it was officially founded in 1989 (noted variably as 1988 or 1989 in sources) in Providence, Rhode Island.[1][5] Key early backers included investors like RS&Co., Hill Carman Ventures, Commonwealth Bioventures, J.P. Morgan Asset Management, and Mayfield, supporting its path to a 1992 IPO.[1] Pivotal moments included collaborations like a 1995 Astra AB deal worth over $30M for chronic pain technology trials in Eastern Europe and a later sale of ECT to Neurotech for $3M upfront plus royalties, enabling a shift to stem cells via its StemCells Inc. subsidiary in Sunnyvale amid headquarters relocation and Rhode Island facility disposals.[2][5]
Cytotherapeutics rode the 1990s biotech wave in cell therapy and encapsulation, a precursor to modern stem cell and regenerative medicine trends, filling gaps in treatments for Parkinson's, diabetes, and chronic pain where cell replacement promised efficacy but faced immune and sourcing hurdles.[1][2] Timing aligned with rising IPO activity and venture interest in neurotech, amplified by partnerships like Astra's $30M+ investment and federal grants later redirected to stem cells.[2][5] Market forces favoring it included unmet needs in CNS disorders and early stem cell hype, influencing the ecosystem by advancing implantable cell tech—now echoed in firms like Neurotech—and paving paths for subsidiaries like Cyto Therapeutics Pty Ltd pursuing Parkinson's trials in Australia with parthenogenetic stem cells.[4] Its Rhode Island roots boosted local biotech dividends despite debts, exemplifying pioneer risks in a field now dominated by scaled players.[5]
Post-restructuring, Cytotherapeutics effectively morphed into stem cell-focused entities, with legacy assets like ECT fueling Neurotech and Australian trials via International Stem Cell Corporation's subsidiary signaling ongoing Parkinson's research (e.g., Phase I safety study).[2][4] Next steps likely involve subsidiary advancements in hpSC-derived therapies amid regenerative medicine's growth, shaped by trends like improved stem cell scalability, AI-driven trial design, and global regulatory harmonization. Its influence may evolve through IP legacies in encapsulation hybrids, potentially amplifying in a market projected to expand with aging populations and gene-editing synergies, tying back to its foundational bet on protected cell transplants as a blueprint for durable biotech innovation.[1][2][4]
